You are here

  • Home
  • Archive
  • Volume 13, Issue 5
  • Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab

Article info

Article menu

Download PDFPDF

Basic and translational cancer immunology
Original research
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab

Authors

  • Christopher J Graser Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Department of Biostatistics, Harvard T H Chan School of Public Health, Cambridge, Massachusetts, USA Department of Stem Cell and Regenerative Biology, Harvard University, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Thomas O McDonald Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Department of Biostatistics, Harvard T H Chan School of Public Health, Cambridge, Massachusetts, USA Department of Stem Cell and Regenerative Biology, Harvard University, Boston, Massachusetts, USA Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Paul J Catalano Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Department of Biostatistics, Harvard T H Chan School of Public Health, Cambridge, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Guru Sonpavde University of Central Florida, Orlando, Florida, USA AdventHealth Cancer Institute, Orlando, Florida, USA PubMed articlesGoogle scholar articles
  • Franziska Michor Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Department of Biostatistics, Harvard T H Chan School of Public Health, Cambridge, Massachusetts, USA Department of Stem Cell and Regenerative Biology, Harvard University, Boston, Massachusetts, USA Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, Massachusetts, USA The Eli and Edythe L Broad Institute, Cambridge, Massachusetts, USA Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Franziska Michor; michor{at}jimmy.harvard.edu; Dr Guru Sonpavde; guru.sonpavde.md{at}adventhealth.com
View Full Text

Citation

Graser CJ, McDonald TO, Catalano PJ, et al
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab
Journal for ImmunoTherapy of Cancer 2025;13:e011740. doi: 10.1136/jitc-2025-011740

Publication history

  • Accepted March 31, 2025
  • First published May 7, 2025.
Online issue publication 
May 07, 2025

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.